Immunology Platform 2012



Similar documents
Guidelines for TB Blood Testing. Minnesota Department of Health TB Prevention and Control Program June 2011

Incidencia y Características Clínicas del Síndrome Inflamatorio de Reconstitución Inmune (IRIS) en el Contexto de la Coinfección VIH-TB

Guideline. Treatment of tuberculosis in patients with HIV co-infection. Version 3.0

What is an IGRA? What is an IGRA? Are they available here? How do I use them? Learning Objectives

Health Protection Agency position statement on the use of Interferon Gamma Release Assay (IGRA) tests for Tuberculosis (TB)

Lisa Y. Armitige, MD, PhD has the following disclosures to make:

CDC TB Testing Guidelines and Recent Literature Update

DRAFT FOR CONSULTATION

Tuberculosis in children in Europe -the ptbnet

Santa Clara County Tuberculosis Screening Requirement for School Entrance Effective June 1, Frequently Asked Questions

TUBERCULOSIS SCREENING AND TREATMENT IN PREGNANCY. Stephanie N. Lin MD 2/12/2016

Journal of Infectious Diseases Advance Access published January 26, 2015

CYP2B6 and NAT2 genetic polymorphisms enlighten the pharmacokinetic interaction of efavirenz with rifampicin and isoniazid - ANRS trial

Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges

TB Intensive San Antonio, Texas November 11 14, 2014

Massachusetts Department of Public Health Division of Global Populations and Infectious Disease Prevention

Pediatric Latent TB Diagnosis and Treatment

Childhood Tuberculosis Some Basic Issues. Jeffrey R. Starke, M.D. Baylor College of Medicine

Pregnancy and Tuberculosis. Information for clinicians

Antiretroviral therapy for HIV infection in infants and children: Towards universal access

Interferon-gamma Release Assays: the Good, the Bad, and the Ugly

Nevada State Health Division Technical Bulletin

Anfumbom KFUTWAH. The Fourth ANRS Yaounde site scien5fic mee5ng. November th 2011

QuantiFERON TB Gold In Tube Method (QGIT Test) Manufacturer: Cellestis Inc. (USA) a QIAGEN Company

Targeted Testing for Tuberculosis Infection

Tuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University

Asthma (With a little SCID to start) Disclosures Outline Starting with the Immune System The Innate Immune System The Adaptive Immune System

The role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015

EMA and Progressive Multifocal Leukoencephalopathy.

GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS IN SOUTH AFRICA

Maria Dalbey RN. BSN, MA, MBA March 17 th, 2015

TB Prevention, Diagnosis and Treatment. Accelerating advocacy on TB/HIV 15th July, Vienna

Understanding the Immune System in Myeloma

HIV Therapy Key Clinical Indicator (KCI)

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO

Policy Directive: compliance is mandatory

Recent Advances in The Treatment of Mycobacterium Tuberculosis

B Cells and Antibodies

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins

Microbiology AN INTRODUCTION EIGHTH EDITION

Chapter 1 Overview of Tuberculosis Epidemiology in the United States

7- Master s Degree in Public Health and Public Health Sciences (Majoring Microbiology)

MODULE THREE TB Treatment. Treatment Action Group TB/HIV Advocacy Toolkit

Frequently Asked Questions

Viral load testing. medical monitoring: viral load testing: 1

Tuberculosis (TB) Screening Guidelines for Substance Use Disorder Treatment Programs in California

Journée des Industriels du Réseau TRIGGERSEP

DIVISION of SUBSTANCE ABUSE SERVICES. Tuberculosis Control Guidelines for Alcohol and Drug Abuse Treatment Programs

TUBERCULOSIS (TB) SCREENING GUIDELINES FOR RESIDENTIAL FACILITIES AND DRUG

Appendix E-- The CDC s Current and Proposed Classification System for HIV Infection

Corporate Medical Policy

Basics of Immunology

CIBMTR Infection Data and the New Infection Inserts.

CME Article Hiv Disease Surveillance

Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation. M Dinaker. Fig.1: Effect of CART on CD4 and viral load

Chapter 43: The Immune System

Tuberculosis. Subject. Goal/Objective. Instructions. Rationale. Operations Directorate, Health Branch Immigration Medical Examination Instructions

The Body s Defenses CHAPTER 24

San Francisco Guidelines on the Use of QuantiFERON-TB Gold (In Tube Method) for the Diagnosis of Latent TB Infection

Chapter 3 Testing for Tuberculosis Infection and Disease

Background paper for SAGE discussions. SAGE non-specific effects of vaccines Working Group

Figure 4.1: Gel picture showing Generation of HIV-1subtype C codon optimized env expressing recombinant plasmid pvax-1:

Challenges in Pediatric Tuberculosis. Mimi Emig, MD Spectrum Health Kent County Health Department

NICHD s Pediatric, Adolescent, & Maternal AIDS Branch

Paediatrica Indonesiana. Limitations of the Indonesian Pediatric Tuberculosis Scoring System in the context of child contact investigation

Tuberculosis OUR MISSION THE OPPORTUNITY

Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March Antti Vuolanto, COO and co-founder

annex 2 country profiles

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

How To Get A Phd At The University Of Sydney

One of the more complex systems we re looking at. An immune response (a response to a pathogen) can be of two types:

The Immune System. 2 Types of Defense Mechanisms. Lines of Defense. Line of Defense. Lines of Defense

Tuberculosis in Myanmar Progress, Plans and Challenges

Corporate Medical Policy

In Tanzania, ARVs were introduced free-of-charge by the government in 2004 and, by July 2008, almost 170,000 people were receiving the drugs.

Treatment of TB a pharmacy perspective

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons

Autoimmunity and immunemediated. FOCiS. Lecture outline

Contact centred strategies to reduce transmission of M. leprae

Richard H. Needle, PhD, MPH Lin Zhao, PhD candidate (UCSF School of Nursing) CSIS Africa Program Roundtable June 10, 2010

Zika Virus. Fred A. Lopez, MD, MACP Richard Vial Professor Department of Medicine Section of Infectious Diseases

GROWTH AND DEVELOPMENT

7- Doctoral Degree in Public Health and Public Health Sciences (Majoring Microbiology)

X-Plain Pediatric Tuberculosis Reference Summary

Biologic Treatments for Rheumatoid Arthritis

Tuberculosis Contact Investigation in a Renal Dialysis Center: Blood Vs. Skin test

QUICK REFERENCE FOR HEALTHCARE PROVIDERS

SCID Pilot Study but first

Personalised Medicine in MS

Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection United States, 2010

How To Help Fight Malaria

Objectives: Immunity Gone Wrong: Autoimmune Diseases in Dental Hygiene Practice

A Genetic Analysis of Rheumatoid Arthritis

HIV Continuum of Care Monitoring Framework 2014

Regulatory Issues in Genetic Testing and Targeted Drug Development

NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum

How To Test For Latent Tuberculosis

Tuberculosis in Children and Adolescents

Global Update on HIV Treatment 2013: Results, Impact and Opportunities

Transcription:

Immunology Platform 2012 The scientific activity report of Immunology Platform of the Institut Pasteur du Cambodge for the period January 1st to December 31st, 2012. Scientific activity report Prepared by: Polidy Pean, Head, Immunology Platform Institut Pasteur du Cambodge, 5, Bvd. Monivong BP 983 - Phnom Penh, Royaume du Cambodge

Research team Team leader: Polidy Pean, MD, PhD Technical staff : Ratana Meng Annual Report ANRS sites in Cambodia 2011-2012 Introduction Cambodia is one of the countries with the highest prevalence of HIV and tuberculosis (TB) infections. An estimation of 64% and 0.7% Cambodian people were infected by TB and HIV-1 respectively, and HIV-1/TB co-infection has increased annually, from 2.5% in 1995 to 10% in 2005. The effective treatments of both infections have reduced the mortality and morbidity. However, simultaneous treatments of both infections were complicated by many problems such as drug toxicity, drug resistance and tuberculosis associated immune reconstitution inflammatory syndrome (TB-IRIS). TB-IRIS occurs in 10 to 25% of patients who were treated with antiretroviral and anti tubercular drugs. It could be an obstacle for antiretroviral therapy management and may have an impact on immune reconstitution in severely immunocompromized patients. Diagnosis of TB-IRIS is very difficult and is always a clinical diagnosis of exclusion. Thus, the understanding of mechanism of TB-IRIS, the impact of TB-IRIS on immune reconstitution and identification of its related biomarkers for prediction and diagnosis of this syndrome is very important. Research Activities in 2011-2012 ANRS 12153 project: Camelia Paradoxical Reaction Immune NK cells study (CAPRI-NK) Principal Investigators: Dr Daniel Scott-Algara (IP Paris) and Dr Eric Nerrienet (IP Cambodia) Partners: CAMELIA Operational Team and CAMELIA clinical investigators) In collaboration with Dr Daniel Scott Algara and his colleagues (Pasteur Institute in Paris) and CAMELIA (Cambodian Early versus Late Introduction of Antiretroviral Drugs) clinical trial team and with the grant support from ANRS 12153, we investigated the implication of innate immunity of NK cells in the onset of IRIS in HIVinfected patients with TB to identify predictive markers of IRIS. As the results, 128 HIV-infected patients with TB from the CAMELIA trial were enrolled in the study. Thirty-seven of the 128 patients developed IRIS. At inclusion, patients had low CD4 cell counts (27cells/mm3) and high plasma viral load (5.76 and 5.50 log/ml in IRIS and non-iris patients, respectively). At baseline, NK-cell degranulation capacity was significantly higher in 2 P a g e

IRIS patients than in non-iris patients (9.6% vs 6.38%, P <0.005). At IRIS onset, degranulation capacity did not differ between patients, whereas activating receptor expression was lower in IRIS patients. Patients with degranulation levels > 10.84% had a higher risk of IRIS (P = 0.002 by log-rank test). Degranulation level at baseline was the most important IRIS predictor (hazard ratio = 4.41; 95% confidence interval, 1.60-12.16). These results have been published in Blood on april 2012. We also investigated NK cell reconstitution in HIV/TB co-infection (IRIS and non-iris patients) at 8 weeks of cart in comparison with HIV mono-infected patients at 6 weeks of cart. As result, we found that NK cell degranulation was similar in TB-IRIS and non TB-IRIS patients following early cart (6 weeks). A trend towards a decrease of total degranulation capacity from baseline to 6 weeks of cart was observed in TB-IRIS and a slightly increase in non TB-IRIS when they were compared to baseline value. By contrast, the total degranulation capacity of NK cell was significantly increased in HIV mono infected patients at 8 weeks of cart (p< 0.001). When delta values of total degranulation were compared, significant differences were found between HIV mono infected patients and IRIS and non IRIS patients (p=0.004 and p<0.001, respectively). We did not detect any increase of the total IFN- secretion by NK cell after target stimulation after 6 weeks of cart in TB/HIV co-infected patients and this is in contrast to those observed in HIV infection alone. In addition, the evolution of CD107a + IFN- + NK cells from baseline to 6/8 weeks of cart has also been found to be low in both TB-IRIS and non-tb-iris group, whereas those in HIV treated patients was increased. Globally, we did not find any difference in term of evolution of NK cell degranulation activity and/or IFN- secretion between TB-IRIS and non TB-IRIS patients during the follow up. A manuscript of those results is in preparation. Research Achievements and Outcomes. Pean P, Nerrienet E, Madec Y, et al. Natural killer cell degranulation capacity predicts early onset of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients with tuberculosis. Blood; 119(14):3315-20. Training: One Cambodian PhD student ( Mr Pean Polidy) has successfully defended his thesis on this project in December 2011 3 P a g e

ANRS 12164 project Camelia Paradoxical Reaction Immune T cells study (CAPRI-T) Principal investigators: Pr Anne Goldfed ( Boston USA), Dr Pean Polidy ( IP Cambodia) Partners: CAMELIA operational team, Camelia clinical investigators, CHC This study is supported by ANRS 12164 and US NIH (for a supplemented grant). In collaboration with Professor Anne Goldfeld s team (Program in Cellular and Molecular Medicine, Children s Hospital-Boston, USA) and CAMELIA clinical trial team, we investigated the immunological basis of TB-IRIS in patients enrolled in CAMELIA clinical trial and its impact on T cell reconstitution. Our aim is to examine the evolution of T cell compartment in TB/HIV co-infected patients (CD4+ T cell counts <200/mm3) enrolled in the trial. We compared the results from patients who developed TB-IRIS within 3 weeks after initiating cart to those who did not develop TB-IRIS (non TB-IRIS). Whole blood T cells immunophenotypes and serum cytokines from 36 TB-IRIS and 104 non-tb- IRIS patients were evaluated prior to ART and at timepoints up to 32 weeks post-art initiation. As the result, in patients who developed TB-IRIS there were significantly higher proportions of activated HLA-DR+CD4+ (p=0.005) and CCR5+CD4+ (p<0.0001) T cells. There were similar levels of activated CD38+CD8+ and regulatory CD4+ T (CD25+/CD127lo) cells in the two groups at cart initiation and at ensuing timepoints. While CD62L- CD45RA- CD4+ effector memory (EM) T cell proportions continued to increase after the TB-IRIS event up to week 32, while in non TB-IRIS patients CD4+EM cell reconstitution stabilized by week 8 post-art (p=0.005). Within the first two weeks post-art, HLA-DR+CD4+ (p=0.0023) and CCR5+CD4+ (p=0.0035) T cell proportions, and serum levels of IL-1 (p=0.026) and IL-6 (p=0.0066), increased at significantly faster rates in TB-IRIS patients as compared to non TB-IRIS patients. In conclusion, global CD4+ T cell activation, elevated CCR5+CD4+ T cell levels and viral load were significantly higher at ART initiation in TB-IRIS patients. The increase in IL-1 and IL-6 after ART initiation in TB-IRIS patients with increased viral antigen load may drive the elevated CD4+ T cell activation in TB-IRIS patient. Research Achievements and Outcomes. Scientific communication: an abstract on Impact of Tuberculosis-Associated IRIS on T Cell Activation and Reconstitution in Highly Immunosuppressed HIV/TB Co-Infected Patients Starting ART has accepted for discussion and poster presentation in 20 th CROI 2013 (US-Atalanta). (Abstract No S-186) Publication: The manuscript of this result is in preparation. Training: One Cambodian PhD student (Mr Pean Polidy) has successfully defended his thesis on this project on december 2011 4 P a g e

ANRS 12 229 Study: Improving diagnosis of Tuberculosis in HIV infected children in Asia (Cambodia, Vietnam) and in Africa (Burkina Faso, Cameroon) (PAANTHER 01) Principal investigators: Dr Olivier Marcy (France), Dr Ung Vibol (Cambodia. Regional Project Manager: Dr Laurence Borand - Country project Manager: Mrs Pheng Phearavin Collaborators: National Pediatric hospital (Phnom Penh) and Angkor Hospital for Children (Siem Reap), Epidemiology and Public Health Unit, Clinical laboratory Unit, Immunology Platform IP Cambodia Childhood tuberculosis (TB) accounts for 11% of the total 9 million annual TB cases and is still not considered a public health priority in endemic countries. The difficulty of diagnosing TB in children is increased in case of HIV infection, in a situation of very high morbidity and mortality and major therapeutic and care issues. The tests currently available in developing countries as well as diagnostic approaches recommended by the national programs or WHO are not sufficiently sensitive and specific. Improved diagnostic criteria are imperative. The new immunological tests measuring the secretion of interferon-gamma (IGRAs) by lymphocytes activated by specific Mycobacterium tuberculosis (MTB) complex antigens are interesting alternatives to the tuberculin skin test (TST), but must be evaluated in immunocompromised children. Our aims is to evaluates the sensitivity, specificity, positive and negative predictive values of an in-vitro Interferon Gamma Release (IGRAs): the QuantiFERON -TB Gold In-Tube, for the diagnosis of TB in HIV infected children and to compare the performances of two in-vitro IGRAs: the QuantiFERON -TB Gold In-Tube and the T.SPOT- TB, for the diagnosis of tuberculosis in HIV infected children in a sub-group of children (in Cambodia). This multicentric study is done in collaboration with Dr Nguyen Thi Ngoc Lan team (Microbiology Laboratory, Pham Ngoc Thach Hospital, Ho Chi Minh City Vietnam), Dr Guislaine Carcelain (Hôpital Pitié-Salpêtrière, Paris, France) and Epidemiology and Public Health Unit of IPC (Dr Laurence Borand) and with grant support from ANRS 12229. On November 30 th, 2012, 84/120 suspected HIV/TB coinfected children were enrolled in Cambodia. The inclusion and data collection are ongoing. 5 P a g e

Perspective: Participation of the Platform of Immunology (Dr PEAN Polidy) and the HIV/Hepatitis Unit (Mr NOUHIN Janin) Impact of maternal HIV infection and feeding mode on the maturation of innate immunity and morbidity in infants in the context of the elimination of MTCT* of HIV-1 in Cambodia (CAMENI) See Report NOUHIN Janin Scientific production Publication: Pean P, Nerrienet E, Madec Y, et al. Natural killer cell degranulation capacity predicts early onset of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients with tuberculosis. Blood; 119(14):3315-20. Scientific communication: an abstract on Impact of Tuberculosis-Associated IRIS on T Cell Activation and Reconstitution in Highly Immunosuppressed HIV/TB Co-Infected Patients Starting ART has accepted for discussion and poster presentation in 20 th CROI 2013 (US-Atalanta). (Abstract No S-186) 6 P a g e